Alyftrek in Sri Lanka

How patients in Sri Lanka access Alyftrek (pegvaliase) via Named Patient Program.

Alyftrek - overview

Alyftrek (pegvaliase) is manufactured by BioMarin Pharmaceutical and indicated for Phenylketonuria. It is a Small molecule approved by the US FDA in 2024 and may be accessible to patients in Sri Lanka through a Named Patient Program or personal-import pathway.

Access in Sri Lanka

Sri Lanka's NMRA permits named-patient import for rare-disease specialty drugs via physician request.

How Reserve Meds coordinates access in Sri Lanka

  1. Patient or treating physician submits a request.
  2. We verify clinical appropriateness and Sri Lanka-specific eligibility.
  3. Treating physician in Sri Lanka issues prescription and clinical justification.
  4. Country-specific NPP/personal-import forms are prepared and filed.
  5. We source Alyftrek from a DSCSA-compliant US specialty wholesaler.
  6. Cold-chain shipment to the patient's physician or hospital pharmacy in Sri Lanka.

Typical timeline for Sri Lanka

End-to-end, most requests are completed in 2-6 weeks. Sri Lanka's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Sri Lanka ask

  • Is the pathway legal in Sri Lanka? Yes - it operates under Sri Lanka's established NPP or personal-import framework.
  • Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
  • What physician credentials do I need? A licensed physician in Sri Lanka able to issue the prescription and clinical justification.
  • What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
  • Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Alyftrek in Sri Lanka

Request Alyftrek

GREEN
AI Regulatory Review Agent — preliminary signal
Small-molecule specialty therapy with clear personal import pathway in Sri Lanka via NMRA. Oral delivery; standard logistics.
Rule: sm_specialty_clear_pathway • Reviewed 2026-04-22

Start an intake request

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (dispensed by Altima Care, US-licensed specialty pharmacy) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp